FindTrial
Sign In

vobramitamab duocarmazine

BIOLOGICAL3 trials

Sponsors

MacroGenics

Conditions

Advanced Solid TumorAdvanced Solid Tumor, AdultAnal CancerAnal NeoplasmAndrogen-Independent Prostatic CancerAndrogen-Insensitive Prostatic CancerAndrogen-Resistant Prostatic CancerCarcinoma, Squamous Cell of Head and Neck

Phase 1

MGC018 With or Without MGA012 in Advanced Solid Tumors
TerminatedNCT03729596
MacroGenicsAdvanced Solid Tumor, Adult, Melanoma, Metastatic Castrate Resistant Prostate Cancer +3
Start: 2018-11-21End: 2023-03-18Updated: 2025-07-31
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
CompletedNCT05293496
MacroGenicsAdvanced Solid Tumor, Castration-Resistant Prostatic Cancer, Epithelial Ovarian Cancer +4
Start: 2022-04-19End: 2025-08-26Updated: 2025-10-14

Phase 2

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
TerminatedNCT05551117
MacroGenicsAnal Cancer, Anal Neoplasm, Androgen-Independent Prostatic Cancer +14
Start: 2023-06-13End: 2025-01-23Updated: 2026-02-09

Related Papers

Vobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion.
2026-08-01
PRECLINICAL ACTIVITY OF THE B7-H3- TARGETING ANTIBODY-DRUG CONJUGATE (ADC) VOBRAMITAMAB DUOCARMAZINE (VOBRA DUO) IN PEDIATRIC SOLID TUMORS
Clinical Cancer Research2026-04-06
Abstract 7040: The B7-H3 targeting antibody-drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) is potently effective against a broad panel of pediatric solid tumor xenograft models: A study from the Pediatric Preclinical In Vivo Testing (PIVOT) Consortium
Cancer Research2025-04-21
757 A phase 1/1b dose escalation and cohort expansion study of MGC018 in combination with lorigerlimab in patients with advanced solid tumors (AST)
Regular and Young Investigator Award Abstracts2022-11-015 citations
Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Journal of Clinical Oncology2021-05-2038 citations
Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors.
Journal of Clinical Oncology2020-05-2020 citations